The global flow cytometry market size was valued at USD 3.98 billion in 2018 and is expected to register a CAGR of 10.6% over the forecast period. Increasing prevalence of chronic diseases, which require toxicity testing, and the need for rapid, accurate, and sensitive prognosis techniques for disease validation are expected to boost the demand for these techniques. Introduction of advanced methods, such as high-throughput multifunctional analysis, rapid detection, higher resolution, and improved cell sorting, ensuring enhanced efficiency in characterizing and identifying novel drugs is also expected to boost market growth.
Extensive R&D for the development of statistical platforms, which are capable of manipulating various parameters, compare all data parameters with many different combinations, customize data analysis strategy, recognize real-time changes in every parameter, and offer figures and graphs with conclusions, will contribute to the product demand further.
In addition, growing awareness and increased healthcare expenditure are likely to have a positive impact on the flow cytometry market. Some of the most common applications of flow cytometry include immunophenotyping, cell sorting, cell proliferation assays, and intracellular calcium flux. The advantages of the technology, such as user-friendliness, are also expected to boost its demand further.
The biotechnology industry is expected to showcase significant growth in the coming years due to increasing healthcare expenditure and improvisation in healthcare facilities. Growing external funding to conduct clinical studies pertaining to the field of in vitro molecular diagnosis is also expected to augment the market, as such initiatives play a vital role in the process of new product development.
Cell-based technology led the overall market in 2018 and is projected to maintain its dominance during the forecast years. Increasing demand for early diagnosis and rising awareness about the benefits of cell-based assays are the factors responsible for its dominance. Moreover, technology has extensive applications in various research fields. These assays are used in drug discovery for the physiological significance of the results.
It is used in clinical studies including tumor cells in peripheral blood, endothelial cells in blood, tumor stem cells, and hematopoietic progenitor cells. Furthermore, they are used in the study of disease mechanism and target identification. Technological advancements in cell-based assays include innovation in instruments, labels, affinity reagents, software, and algorithms. For example, automated microcapillary cytometry, which was recently introduced, is a time-saving and cost-effective procedure for cell analysis study.
Furthermore, this technique combines the ability of bioinformatics and robotics. The aforementioned factors are expected to fuel the segment growth in the near future. Bead-based assays are developed to study infectious diseases. Demand for these assays is expected to increase owing to constant advancements in molecular engineering, monoclonal antibody production, and associated advantages, such as cost-efficiency, low sample requirement, and short turnaround time. These assays are described as indirect or sandwich immunoassay formats, which are specifically used for measuring antibody levels in biological fluids.
The instrument was the dominant segment in 2018 and is likely to retain the leading position owing to greater penetration coupled with advantages, such as accurate result and user-friendliness. However, reagents and consumables, owing to their increased usage in cancer diagnostics, are expected to register the maximum CAGR from 2019 to 2026.
Instruments used for flow cytometry include cell analyzers, cell sorters, and sample preparation devices, such as platforms for cell analysis and replaceable components like filters, lasers, and detectors. The introduction of novel technologies, such as multicolor flow cytometers, coupled with their capability to detect up to 18 cell parameters simultaneously is one of the factors contributing to the demand.
Reagents & consumables are anticipated to witness the highest CAGR over the forecast period due to extensive utilization in diagnostics applications. Reagents and consumables include antibodies and buffers for research on cell biology and immunology, dyes, beads, recombinant proteins for measuring cellular functioning, such as cell cycle, apoptosis, & proliferation, bioimaging reagents for cellular imaging & clinical research, protein expression, and in cell separation procedures.
Clinical diagnostic reagents, such as multicolor cocktails, ASR reagents, and purified antibodies, are used in disease diagnosis. The segment is anticipated to witness steady growth due to increasing demand for sensitive assays, fluorescent dyes, and antibodies for identifying new biomarkers in the development of new vaccines and therapeutics.
Growth in the biotechnology sector is expected to boost the cytometry market. Furthermore, it is also expected to witness growth due to its wide applications in different fields including cell culture, drug discovery, and stem cell therapy. Research application held the largest revenue share in the past owing to increased R&D activities pertaining to cancer and other infectious diseases. This technology is widely used in the pharmaceutical research segment and also has applications in various industries, such as food microbiology and plant tissue culture.
Increasing demand for faster and accurate cancer prognostic tools and the rising prevalence of the disease is the key factors attributing for its large share. Research pertaining to drug development, stem cell therapy, and in vitro toxicity testing are also expected to fuel the demand for this technology. Clinical diagnosis is expected to be the fastest-growing application segment from 2019 to 2026 due to the factors, such as increasing demand for cost-effective disease diagnostic tools and the benefits of these assays in disease detection.
Increasing demand for companion diagnostics and personalized medicine thrives in tandem with the growth of applications of cytometry for the life science industry. The rising number of healthcare organizations promoting the usage of high-quality diagnostics is presumed to be responsible for the share captured by this segment over the previous years. For instance, the Medical College of Wisconsin in collaboration with Jeffrey Modell Foundation issued a draft on clinical cytometry in the diagnosis of primary immunodeficiencies. This draft was launched to promote awareness amongst physicians about cytometric tests used for early diagnosis of PIDDs and methodologies as per clinical indication.
The commercial organization segment held the largest revenue share in 2018 owing to wide applications across various verticals, such as food microbiology, blood banks, and plant cell culture. The introduction of multiplex probes and reagents for specific applications in diagnostics and drug discovery is expected to offer numerous growth opportunities for the segment by catering to the users in research and small peripheral laboratories.
The hospital segment is expected to register the maximum CAGR from 2019 to 2026 due to supportive reimbursement policies, growing awareness, and increasing need for diagnostic tests as a result of the rising prevalence of chronic and infectious diseases. In April 2015, London Cancer Alliance launched clinical guidelines for haemato-oncology, such as plasma cell disorders. These guidelines also focus on the usage of flow cytometers as diagnostics, thus promoting awareness amongst clinicians and pathologists.
These factors are anticipated to boost the adoption of this technology. Increasing incidence of chronic conditions in developing countries has been driving the demand for faster diagnostic tools. According to the WHO statistics, in 2018, communicable diseases accounted for around 11% of the mortality rate in Latin America. Thus, growing cases of communicable diseases and unmet clinical needs are expected to drive the demand for cytometry.
North America led the overall cytometry market in 2018 owing to the presence of supportive government reforms for the development of advanced technologies for molecular diagnostics. It projected to maintain dominance over the forecast years on account of the availability of skilled professionals and higher awareness levels. The U.S. is the largest market in North America owing to the high incidence of cancer and other chronic conditions. Moreover, the presence of a large number of clinical research labs and major pharmaceuticals in the U.S. is likely to contribute to the country’s growth.
Asia Pacific region is presumed to witness the fastest CAGR in the coming years owing to supportive government funding for the biotech industry development. In addition, the presence of untapped opportunities, constantly improving healthcare infrastructure, rapid economic development, and rising patient awareness levels are further estimated to drive the regional market. Continuous R&D activities for cancer treatment in the region, facilitating the demand for cytometry, is also boosting the region’s growth. Moreover, the rising adoption of new techniques for molecular-based cytogenetics, increasing outsourcing activities, and growing demand for early diagnosis and detection of diseases will spur the market.
Some of the key companies in the market are Beckman Coulter, Inc.; Becton, Dickinson and Company; Sysmex Corporation; Agilent Technologies; Merck & Co., Inc.; Apogee Flow Systems Ltd.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific; Stratedigm, Inc.; Luminex Corporation; Miltenyi Biotec; and GE Healthcare. The market is highly competitive as key companies are involved in continuous product development and partnership alliances to aid market penetration. Furthermore, increasing number of outsourcing service providers is expected to intensify the competition. Companies are also focusing on setting up manufacturing plants in emerging regions to gain profits.
For instance, in September 2015, BD Life Sciences entered into a collaborative agreement with Seegene Inc. for the development of multiplex real-time PCR reagents for the BD max system in a probe to gain competitive advantage. Increasing R&D investments in biotechnology sector and strategic collaborations coupled with introduction of upgraded systems are anticipated to propel the market. For instance, in March 2017, Beckman Coulter Life Sciences launched its latest model CytoFLEX LX with six lasers and 21 fluorescent channels as an upgradation to its existing portfolio.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, China, India, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE, Turkey, Iran
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global flow cytometry market report on the basis of technology, product & services, application, end-use, and region:
Technology Outlook (Revenue, USD Million, 2014 - 2026)
Product & Services Outlook (Revenue, USD Million, 2014 - 2026)
Reagent & Consumables
Application Outlook (Revenue, USD Million, 2014 - 2026)
In Vitro Toxicity
Cell Cycle Analysis
End-Use Outlook (Revenue, USD Million, 2014 - 2026)
Clinical Testing Labs
Regional Outlook (Revenue, USD Million, 2014 - 2026)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.